Zobrazeno 1 - 10
of 138
pro vyhledávání: '"Stanley P. Balcerzak"'
Publikováno v:
Scandinavian Journal of Haematology. 3:245-256
Increased erythrocyte catalase activity per gram haemoglobin or per milliliter red cells was found in all 32 patients with thalassaemia minor, and in 2 of 7 patients with thalassaemia major. The trait was associated with increased catalase activity e
Publikováno v:
Scandinavian Journal of Haematology. 3:205-212
In confirmation of previous work oral administration of an iron-chelating substance, deferoxaminum (DFO), was found to reduce absorption of inorganic but not haemoglobin iron. Retention of ionic iron was impaired whether the iron and DFO were mixed i
Autor:
Cathryn Rankin, Stanley P. Balcerzak, Shaker R. Dakhil, Howard R. Terebelo, Frederick R. Appelbaum, Cheryl L. Willman, Anand B. Karnad, Stephen H. Petersdorf, David R. Head
Publikováno v:
American Journal of Hematology. 82:1056-1062
Induction therapy for acute myeloid leukemia (AML) usually consists of 7 days of cytarabine at 100–200 mg/m2/day and an anthracycline. Such combinations produce complete response (CR) rates of 60–80% in patients with de novo AML. On the basis of
Autor:
James L. Abbruzzese, Robert P. Whitehead, Stanley P. Balcerzak, Bach Ardalan, Jacqueline Benedetti, Ellen R. Gaynor, Stephen K. Williamson, John S. Macdonald
Publikováno v:
Investigational New Drugs. 22:467-473
Purpose: The purpose of this phase II multi-institutional study was to define the efficacy and toxicity of infusional 5-FU in combination with PALA and leucovorin in patients with advanced colorectal cancer. Patients and methods: Patients were requir
Autor:
James L. Abbruzzese, John S. Macdonald, Stanley P. Balcerzak, Bach Ardalan, Robert P. Whitehead, J. Wendall Goodwin, Heinz-Josef Lenz, Jacqueline Benedetti, Wolfram E. Samlowski
Publikováno v:
Investigational New Drugs. 22:335-341
Purpose: The purpose of this phase II multi-institutional study was to define the efficacy and toxicity of infusional 5-FU in combination with PALA and leucovorin in patients with advanced pancreatic cancer. Patients and methods: Patients were requir
Autor:
G. Thomas Budd, Peter M. Ravdin, Stanley P. Balcerzak, Gary H. Lyman, Stephanie Green, Charles E. Geyer, Silvana Martino, Christy A. Russell
Publikováno v:
Breast Cancer Research and Treatment. 85:143-150
Purpose. To evaluate whether the high complete response (CR) rates for the combination of doxorubicin and paclitaxel in metastatic breast cancer observed in two European studies could be replicated in a multi-institutional cooperative group trial. Pa
Autor:
Edward L. Middleman, Susan M. Talbot, Karen H. Antman, H D O Laurence Baker, Stanley P. Balcerzak, Robert A. Chapman, Nirmala Bhoopalam, Robert N. Taub, Cathryn Rankin
Publikováno v:
Cancer. 98:331-336
BACKGROUND The current study was conducted to assess the activity and toxicity of high-dose ifosfamide and mesna with recombinant human granulocyte–colony-stimulating factor (rhG-CSF), given in an outpatient setting, in the treatment of patients wi
Combination of Fludarabine and Mitoxantrone in Untreated Stages III and IV Low-Grade Lymphoma: S9501
Autor:
C. Harris Spiridonidis, Keith S. Lanier, Danika Lew, Shaker R. Dakhil, Richard I. Fisher, Thomas M. Grogan, Robert A. Chapman, Stanley P. Balcerzak, William S. Velasquez, Thomas P. Miller
Publikováno v:
Journal of Clinical Oncology. 21:1996-2003
Purpose: To determine the efficacy of combination fludarabine and mitoxantrone (FN) in untreated stages III and IV low-grade lymphoma. The major end point was to estimate progression-free survival (PFS) in all eligible patients. Patients and Methods:
Autor:
Stanley P. Balcerzak, Kenneth K. Chan, Eric H. Kraut, Steven M. D'Ambrosio, Jing Liu, Michael R. Grever
Publikováno v:
Cancer Chemotherapy and Pharmacology. 50:445-453
Background. In a phase I clinical trial of oxaliplatin (OPT) in combination with paclitaxel (PXL), a pharmacokinetic interaction was observed when OPT was given as a 2-h i.v. infusion followed by a 1-h i.v. infusion of PXL. The purpose of this study
Autor:
Stanley P. Balcerzak, Dale D. Vandre, Eric H. Kraut, Sharon Galloway, Timothy Moore, Jason P. Thomas
Publikováno v:
Cancer Investigation. 20:192-198
CI-980, (ethyl (S)-(5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b] pyrazine-7-yl) carbamate 2-hydroxyethansulfonate (1:1)), is a water-soluble mitotic inhibitor. It acts by binding to the colchicine-binding site on tubulin, a site different from